• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Bruker Launches Transformative neofleX™ MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications

    6/3/24 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email
    • neofleX is a versatile, high-performance, and easy-to-use multiomics MSI system for biopharma, translational and clinical researchers
    • neofleX Imaging Profiler MALDI-TOF/TOF with proprietary smartbeam 3D laser
    • neofleX and MALDI HiPLEX-IHC technology enable protein tissue imaging
    • Multiomics MSI correlation of targeted proteins with glycans, metabolites, lipids, endogenous peptides, and now also mid-plex mRNA/DNA-ISH
    • More insights per pixel with new SCiLS™ Scope software and OME-TIFF output

    At the 72nd ASMS meeting, Bruker Corporation (NASDAQ:BRKR) announced the launch of a novel, high-performance MALDI-TOF/TOF system, the neofleX Imaging Profiler for mass spectrometry-based tissue imaging. It enables facile OME-TIFF file output via the new SCiLS Scope software. The transformative neofleX MALDI-TOF/TOF MSI system now conveniently fits on a bench-top.

    This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240603327426/en/

    neofleX MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications (Photo: Business Wire)

    neofleX MALDI-TOF System for Spatial Biology Mass Spec Imaging (MSI) Applications (Photo: Business Wire)

    The neofleX Imaging Profiler MALDI-TOF/TOF mass spectrometer comes standard with Bruker's proprietary 10 kHz smartbeam 3D laser for true pixel fidelity and with enhanced imaging detectors designed for longitudinal robustness, stability, and reproducibility in linear and reflector modes. neofleX is also available as a TOF/TOF configuration that features a reimagined fragmentation module for significantly improved TOF/TOF sensitivity, speed and sequence coverage.

    Created for the unmet needs of moving from discovery imaging to translational and clinical tissue research, neofleX was used by the group of Prof. Bernd Bodenmiller at ETH and University of Zuerich to simultaneously map 116 proteins across a lung FFPE tissue section in 7 hours, using the MALDI HiPLEX-IHC workflow. Multiplexed detection with neofleX and MALDI HiPLEX-IHC technology allows increasing the number of proteins to map cellular processes without increasing MSI measurement time for a given region of interest.

    In addition to MALDI HiPLEX-IHC MSI immunohistochemistry, neofleX is also compatible with the MALDI-ISH (in situ hybridization) method announced at ASMS 2024 by AmberGen, Inc. MALDI-ISH multiplexes imaging of up to 12 oligomers of interest (RNA/DNA) for multiomic spatial tissue research in neuroscience, infectious disease, and oncology.

    The novel neofleX excels at providing more insight per pixel through multiomic spatial biology data from tissue sections that can positively correlate targeted proteins with glycans, metabolites, lipids, endogenous peptides, xenobiotics, and now RNA/DNA. This additional multiomics context provides important adjacency information about cellular states, function, structure, and protein activity for a range of research areas, such as oncology and neurology.

    Professor Carsten Hopf of the University of Mannheim, Germany, Center for Mass Spectrometry and Optical Spectroscopy (CeMOS) commented: "The innovative neofleX presents an incredibly powerful, versatile and easy-to-use mass-spec imaging system for tissue spatial biology researchers for targeted proteomics. We appreciate the value of this instrument for performance and versatility, and our clinical research collaborators welcome the translational research capabilities."

    Multiomic co-localization of lipids and glycans on a tissue section allows to not only localize protein targets using MALDI HiPLEX-IHC, but also assess protein activity and function. A study performed at CeMOS on brain tissues from a transgenic mouse model demonstrated co-localization of amyloid β-42 (Aβ42) protein with a targeted membrane-bound glycosphingolipid (GM3 d36:1), yielding important structural information.

    Dr. Michael L. Easterling, Vice President MSI for Bruker's Life Sciences Mass Spectrometry division, commented: "The neofleX offers unique combination of outstanding performance, multimodal software and workflows on the benchtop for a wide range of biopharma and clinical researchers. Additionally, neofleX brings novel capabilities to spatial biology, including spatial proteomics combined with unique multiomics correlations for developing actionable biological insights."

    The neofleX is compatible with Bruker's MALDI Imaging software and consumables ecosystems, such as IntelliSlides™ and SCiLS autopilot that simplify sample tracking, preparation, and analysis and require minimal input from users to initiate and process automated mass-spec imaging runs. For ease of collaborations, the neofleX now delivers targeted imaging data via automatically generated OME-TIFF images that can be viewed within the SCiLS environment, or easily exported into custom pipelines or digital pathology systems.

    Bruker also announced extension of the SCiLS portfolio with SCiLS Scope 1.0 for collaboration around targeted, multiomic translational workflows developed for neofleX. SCiLS Scope software supports OME-TIFF datasets from targeted imaging workflows such as MALDI HiPLEX-IHC. Ion images are visualized by false-color coding of selected channels, and image processing and distance measurements can be accomplished with simple tools.

    Blaine R. Roberts, Ph.D., Associate Professor in the Department of Biochemistry and Department of Neurology at Emory University in Atlanta, GA, summarized: "Fast and user-friendly visualization of targets is made easy by the addition of SCiLS Scope to the MSI software lineup."

    About Bruker Corporation – the Emerging Leader of the Post-Genomic Era (NASDAQ:BRKR)

    Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240603327426/en/

    Get the next $BRKR alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    5/22/2025$40.00Buy → Neutral
    Citigroup
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    9/30/2024Outperform → Peer Perform
    Wolfe Research
    8/28/2024$78.00Overweight
    Wells Fargo
    6/3/2024$85.00Buy
    Jefferies
    More analyst ratings

    $BRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/14/24 1:28:29 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/13/24 6:01:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13G/A filed by Bruker Corporation

      SC 13G/A - BRUKER CORP (0001109354) (Subject)

      11/12/24 11:54:03 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Financials

    Live finance-specific insights

    See more
    • Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics

      Acquisition further expands Bruker's multiomics strategy with biocrates metabolomics kits and assays, and related software and research services Bruker Corporation (NASDAQ:BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603323690/en/biocrates kits and pipettes biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits co

      6/3/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Quarterly Dividend

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on June 27, 2025 to stockholders of record as of June 16, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscop

      5/15/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Reports First Quarter 2025 Financial Results

       Q1 2025 revenues of $801.4 million, up 11.0% year-over-year; organic revenue up 2.9%, and constant-exchange rate (CER) revenue up 12.5%; Bruker Scientific Instrument (BSI) segment organic revenue up 5.1% Q1 2025 GAAP diluted EPS $0.11; non-GAAP diluted EPS $0.47, down 11.3% yoy on M&A headwinds Guidance on organic revenue and EPS adjusted for US policy changes and tariff headwinds. Updated FY 2025 guidance: Revenue $3.48 to $3.55 billion, up 3.5% to 5.5%, incl. organic growth of 0% to 2% Non-GAAP EPS $2.40 to $2.48, growth of 0% to 3% yoy Bruker Corporation (NASDAQ:BRKR) today announced financial results for its first quarter ended March 31, 2025. Frank H. Laukien, Bruker's

      5/7/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bruker Applied MS Unveils Strategic Innovations at ASMS 2025, Showcasing Advances in DART Technology for TDM and DoA Analysis and Launching timsMetabo™ for PFAS and Environmental Contaminant Detection

      Bruker strengthens its applied markets leadership with RECIPE majority investment and unveils timsMetabo™, a next-generation platform for high-sensitivity small molecule analysis Bruker Corporation (NASDAQ:BRKR) today announced that its Applied Mass Spectrometry (Applied MS) division will present a powerful lineup of innovations at the 73rd American Society for Mass Spectrometry (ASMS) Conference, taking place June 1–5, 2025, in Baltimore, Maryland. These developments reflect Bruker's continued investment in applied markets, particularly in therapeutic drug monitoring (TDM), drugs of abuse (DoA) analysis and environmental analysis. This press release features multimedia. View the full re

      6/3/25 11:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics

      Acquisition further expands Bruker's multiomics strategy with biocrates metabolomics kits and assays, and related software and research services Bruker Corporation (NASDAQ:BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603323690/en/biocrates kits and pipettes biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits co

      6/3/25 7:00:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Launches New timsUltra AIP System with Further Enhanced, Extreme Sensitivity for Single-Cell Proteomics, FNA Biopsy Immunopeptidomics and Metaproteomics

      Breakthrough Athena Ion Processor (AIP) delivers up to 35% more peptide and 20% more protein identifications for highest sensitivity proteomics At the 73rd Conference on Mass Spectrometry and Allied Topics (ASMS), Bruker Corporation (NASDAQ:BRKR) today announced significant further advances in ultra-high sensitivity 4D-Proteomics™ with the introduction of the timsUltra AIP mass spectrometer. Its innovative, breakthrough Athena Ion Processor (AIP) technology further boosts the extreme sensitivity of timsTOF Ultra PASEF® methods for key biological and clinical research problems with very low sample amounts. This press release features multimedia. View the full release here: https://www.bus

      6/2/25 7:01:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    SEC Filings

    See more
    • SEC Form SD filed by Bruker Corporation

      SD - BRUKER CORP (0001109354) (Filer)

      5/30/25 4:07:43 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Corporation filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - BRUKER CORP (0001109354) (Filer)

      5/29/25 4:34:19 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form DEFA14A filed by Bruker Corporation

      DEFA14A - BRUKER CORP (0001109354) (Filer)

      5/19/25 8:00:04 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      3/11/25 4:11:27 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      2/19/25 4:23:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • PRESIDENT & CEO Laukien Frank H bought $5,014,069 worth of shares (100,000 units at $50.14), increasing direct ownership by 0.26% to 38,439,563 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      11/19/24 4:07:19 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Director Francis Laura was granted 4,498 shares (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      5/19/25 5:08:26 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Ornell John A exercised 5,000 shares at a strike of $18.15, increasing direct ownership by 19% to 31,445 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      5/14/25 4:12:44 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Linton William A exercised 10,000 shares at a strike of $24.00, increasing direct ownership by 21% to 58,723 units (SEC Form 4)

      4 - BRUKER CORP (0001109354) (Issuer)

      4/24/25 4:15:05 PM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker downgraded by Citigroup with a new price target

      Citigroup downgraded Bruker from Buy to Neutral and set a new price target of $40.00

      5/22/25 8:18:13 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Guggenheim initiated coverage on Bruker with a new price target

      Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00

      12/19/24 7:30:10 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • UBS initiated coverage on Bruker with a new price target

      UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00

      12/10/24 8:26:42 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $BRKR
    Leadership Updates

    Live Leadership Updates

    See more
    • Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

      ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

      4/23/25 6:15:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Bruker Appoints Laura Francis to its Board of Directors

      Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

      2/21/25 8:00:00 AM ET
      $BRKR
      $PGNY
      $SIBN
      $SWAV
      Biotechnology: Laboratory Analytical Instruments
      Industrials
      Misc Health and Biotechnology Services
      Health Care
    • Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

      Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

      4/4/24 8:11:00 AM ET
      $BRKR
      Biotechnology: Laboratory Analytical Instruments
      Industrials